Research article · 19 Aug 2025
Conference abstractPublished 11 Aug 2015
Amplifying the role of collaboration globally for neglected and commercial disease drug discovery
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Collaborative innovation is uniquely able to realize the economics of well-integrated specialization required for drug discovery. Particularly in the neglected infectious disease areas lacking a profit motive, better collaborative tools are fundamentally important to catalyze faster progress. Layering unique collaborative capabilities upon requisite drug discovery database functionality unlocks and amplifies synergy between biologists and chemists. Researchers need to have tools that balance individual needs for robust, intuitive registration and bioactivity analyses while at the same time facilitating collaborations with secure data partitioning, communication, and group engagement. Since collaborative technology is “therapeutic area agnostic”, it has generally been proven equally applicable for commercial applications. Representative commercial case studies include broad consortia such as the NIH Neuroscience Blueprint collaboration between drug discovery companies, CROs, together with seven leading academic biology laboratories as part of a 5-year government contract to advance new CNS drugs into the clinic. As well as more focused examples following the lean venture funded model such as the collaboration between Acetyton Pharmaceuticals with Harvard and a Chinese CRO to bring a selective HDAC inhibitor into the clinic. Finally, by spanning the continuum of private, collaborative and public modes, researchers globally can now seamlessly collaborate across the pre-competitive and competitive landscape.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Drug Designing: Open Access.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Barbara Holtz”
- BylineArticles whose byline prints “Charlie Weatherall”
- BylineArticles whose byline prints “Barry Bunin”
